CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Vanda Pharmaceuticals
VNDA
$275M
| $6.36K | ﹤0.01% |
1,472
+719
| +95% | +$3.11K |
|
|
KLRS
377
Kalaris Therapeutics, Inc. Common Stock
KLRS
$81.5M
| $6.27K | ﹤0.01% |
127
+74
| +140% | +$3.66K |
|
378
Acumen Pharmaceuticals
ABOS
$84.2M
| $6.15K | ﹤0.01% |
1,481
+943
| +175% | +$3.91K |
|
379
Monte Rosa Therapeutics
GLUE
$306M
| $6.13K | ﹤0.01% |
1,280
+633
| +98% | +$3.03K |
|
380
Enanta Pharmaceuticals
ENTA
$192M
| $6.12K | ﹤0.01% |
548
+272
| +99% | +$3.04K |
|
381
Immuneering
IMRX
$231M
| $5.75K | ﹤0.01% |
749
+366
| +96% | +$2.81K |
|
382
ATAI Life Sciences
ATAI
$984M
| $5.49K | ﹤0.01% |
4,258
+2,083
| +96% | +$2.69K |
|
383
Foghorn Therapeutics
FHTX
$308M
| $5.37K | ﹤0.01% |
1,073
+525
| +96% | +$2.63K |
|
384
Sutro Biopharma
STRO
$86.5M
| $5.37K | ﹤0.01% |
1,546
+754
| +95% | +$2.62K |
|
385
Fate Therapeutics
FATE
$112M
| $5.36K | ﹤0.01% |
2,526
+1,236
| +96% | +$2.62K |
|
|
PSTX
386
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $5.3K | ﹤0.01% |
2,225
+1,088
| +96% | +$2.59K |
|
|
EGRX
387
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $5.27K | ﹤0.01% |
334
+162
| +94% | +$2.56K |
|
388
Quantum-Si Incorporated
QSI
$219M
| $5.19K | ﹤0.01% |
3,127
+1,534
| +96% | +$2.55K |
|
|
EXAI
389
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $5.16K | ﹤0.01% |
1,141
+565
| +98% | +$2.55K |
|
|
CMPS
390
Compass Pathways
CMPS
$485M
| $5.11K | ﹤0.01% |
690
+377
| +120% | +$2.79K |
|
|
TSVT
391
DELISTED
2seventy bio
TSVT
| $5.1K | ﹤0.01% |
1,300
+642
| +98% | +$2.52K |
|
392
ALX Oncology
ALXO
$56.8M
| $5.07K | ﹤0.01% |
1,056
+520
| +97% | +$2.5K |
|
|
ALLK
393
DELISTED
Allakos
ALLK
| $5.05K | ﹤0.01% |
2,225
+1,091
| +96% | +$2.48K |
|
|
GRCL
394
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $5.03K | ﹤0.01% |
1,748
+855
| +96% | +$2.46K |
|
395
Gossamer Bio
GOSS
$575M
| $4.81K | ﹤0.01% |
5,774
+4,523
| +362% | +$3.77K |
|
396
Invivyd
IVVD
$202M
| $4.79K | ﹤0.01% |
2,816
+1,381
| +96% | +$2.35K |
|
397
Omeros
OMER
$287M
| $4.73K | ﹤0.01% |
1,619
+795
| +96% | +$2.32K |
|
398
Stoke Therapeutics
STOK
$1.08B
| $4.46K | ﹤0.01% |
1,132
+553
| +96% | +$2.18K |
|
399
Texas Roadhouse
TXRH
$11.3B
| $4.23K | ﹤0.01% |
44
| – | – |
|
400
Cartesian Therapeutics
RNAC
$263M
| $4.17K | ﹤0.01% |
131
+64
| +96% | +$2.04K |
|